Safety Parameter: Adverse Events Until study termination; 3 years [clinicaltrials_resource:6404a11859cbd012f542e352fe94b31c]
Phase 1B: To determine the MTD of E7080 in combination with carboplatin and gemcitabine as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7080. Phase II: Safety and tolerability of E7080 at the MTD determined in Phase Ib in combination with carboplatin and gemcitabine as measured by rate of adverse events by body system and grade.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Safety Parameter: Adverse Events Until study termination; 3 years [clinicaltrials_resource:6404a11859cbd012f542e352fe94b31c]
Phase 1B: To determine the MTD of E7080 in combination with carboplatin and gemcitabine as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7080. Phase II: Safety and tolerability of E7080 at the MTD determined in Phase Ib in combination with carboplatin and gemcitabine as measured by rate of adverse events by body system and grade.
Bio2RDF identifier
6404a11859cbd012f542e352fe94b31c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6404a11859cbd012f542e352fe94b31c
measure [clinicaltrials_vocabulary:measure]
Safety Parameter: Adverse Events
time frame [clinicaltrials_vocabulary:time-frame]
Until study termination; 3 years
description
Phase 1B: To determine the MTD ...... ents by body system and grade.
identifier
clinicaltrials_resource:6404a11859cbd012f542e352fe94b31c
title
Safety Parameter: Adverse Events Until study termination; 3 years
@en
type
label
Safety Parameter: Adverse Even ...... 4a11859cbd012f542e352fe94b31c]
@en